Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline

Feb 23, 2026, 3:27 PM

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He spe...

Redirecting to full article...